Having trouble accessing articles? Reset your cache.

Raxone idebenone regulatory update

Santhera withdrew an MAA for Raxone idebenone to treat Leber's hereditary optic neuropathy (LHON). The company said it plans to submit a new

Read the full 230 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE